Invasion of human erythrocytes by Plasmodium vivax requires interaction between Duffy binding protein (PvDBP) and the Duffy blood group antigen. The receptor-binding domain of PvDBP lies in a conserved N-terminal, cysteine-rich region, region II (PvRII). PvRII is a valuable malaria subunit vaccine candidate for asexual blood stages. We have evaluated in Aotus monkeys the immunogenicity and protective efficacy of recombinant PvRII formulated in Freund's and Montanide ISA720 adjuvants. Specific antibody titers were determined by an enzyme-linked immunosorbent assay after each of three doses of 50 microg of protein administered by the subcutaneous route. Immunization with PvRII formulated in Freund's adjuvant yielded higher antibody titers than immunization with the Montanide ISA720 formulation and offered partial protection. Although the Montanide ISA720 formulation was immunogenic, it did not provide any protection. Given the immunogenicity and partial protection observed, further studies are needed to optimize the PvRII vaccine formulation with adjuvants suitable for human use.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4269/ajtmh.2005.73.5_suppl.0730025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- The study investigated the use of engineered outer membrane vesicles (OMVs) from ClearColi™ as both an adjuvant and a carrier for a novel vaccine targeting HIV-1 antigens Nef and Nef-Tat.
- Researchers isolated recombinant OMVs (rOMVs) containing specific fusion proteins and confirmed their presence through western blotting.
- Results showed that rOMVs induced stronger immune responses, including higher levels of IgG2a and IFN-γ, compared to traditional adjuvants, indicating their potential as effective vaccine carriers against HIV-1.
Determination of the safety and efficacy of recombinant Chlamydia muridarum MOMP vaccines, formulated with CpG-1826 and 70%, 50%, 30% or 10% concentrations of Montanide ISA-720 VG, to elicit protective immune responses against a C. muridarum respiratory challenge.
Res Sq
December 2023
Lawrence Livermore National Laboratory.
To determine the safety and protective efficacy of a MOMP vaccine, formulated with CpG-1826 and four different concentrations of Montanide ISA 720 VG (70%, 50%, 30% and 10%), BALB/c mice were immunized twice intramuscularly. Local reactogenicity was significant for vaccines formulated with 70% and 50% Montanide but not in mice receiving 30% and 10% Montanide. Robust humoral and cell mediated memory immune responses were elicited by the 70%, 50% and 30% Montanide formulations.
View Article and Find Full Text PDFComparison of Adjuvant Effects of Montanide ISA-720 and Heat Shock Protein 27 in Increasing Immunostimulatory Properties of HIV-1 Nef-Vif Fusion Protein Construct.
Protein Pept Lett
July 2023
Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
Article Synopsis
- Effective T-cell immunity plays a crucial role in HIV-1 vaccination, specifically targeting proteins like Nef and Vif that aid the virus in evading the immune system.
- The study aims to compare the immunostimulatory effects of Montanide ISA-720 and heat shock protein 27 (Hsp27) on an HIV-1 Nef-Vif fusion protein as a potential vaccine.
- Results showed that Hsp27 significantly enhanced immune responses, generating higher levels of antibodies and signaling molecules compared to the commercial adjuvant Montanide ISA-720, suggesting its effectiveness for future vaccine development against HIV-1.
Peptide emulsions in incomplete Freund's adjuvant create effective nurseries promoting egress of systemic CD4 and CD8 T cells for immunotherapy of cancer.
J Immunother Cancer
September 2022
ISA Pharmaceuticals, Leiden, The Netherlands
Water-in-oil emulsion incomplete Freund's adjuvant (IFA) has been used as an adjuvant in preventive and therapeutic vaccines since its development. New generation, highly purified modulations of the adjuvant, Montanide incomplete seppic adjuvant (ISA)-51 and Montanide ISA-720, were developed to reduce toxicity. Montanide adjuvants are generally considered to be safe, with adverse events largely consisting of antigen and adjuvant dose-dependent injection site reactions (ISRs).
View Article and Find Full Text PDFMontanide ISA-720 and Naloxone in HBsAg Vaccine Formulation: Cytokine Profiling and Monitoring of Long-Lasting Humoral Immune Responses.
Biomed Environ Sci
September 2022
Advanced Therapy Medicinal Product (ATMP) Department, Breast Cancer Research Center, Motamed Cancer Institute, Academic Center for Education, Culture and Research (ACECR), Tehran, Iran;Recombinant Vaccine Research Center, Tehran University of Medical Sciences, Tehran, Iran;Department of Immunology, Pasteur Institute of Iran, Tehran, Iran;Immunotherapy Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
Objective: This study aimed to investigate the effects of Montanide ISA-720 and Naloxone (NLX) in Hepatitis B surface antigen (HBsAg) vaccine formulation on cytokine and long-lasting antibody responses.
Methods: First, the HBsAg was formulated in Montanide ISA-720 adjuvant and Naloxone at 5 and 10 mg/kg. The experimental mice were immunized three times at a 2-week interval, and then IL-4, IL-2, TNF-α, and IFN-γ cytokines; long-lasting IgG antibody responses 220 days after the last shot; and IgG1/IgG2a isotypes were assessed by ELISA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!